Introduction {#s1}
============

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to be the subject of global attention due to the serious threat it poses to public health ([@B79]; [@B96]). Currently, there are no specific drugs available to combat SARS-CoV-2 ([@B44]). The epidemic is ongoing and, as of 12 June, 2020, the World Health Organization (WHO) reported that there had been 7,410,510 confirmed cases worldwide, including 418,294 deaths ([@B18]).

This means that more aggressive trials of drugs to prevent and treat SARS-CoV-2 infection should be intensely pursued across the globe ([@B39]). Therefore, there is an urgent need to identify agents for treating SARS-CoV-2 infection ([@B45]). As a major source for drugs and drug leads, natural products and natural-product-inspired agents have attracted significant attention, and they have played an integral role in the treatment of many different conditions ([@B52]). Since the start of the multinational COVID-19 outbreak, significant progress has been made in identifying natural products and natural-product-inspired small molecules that may serve as anti-SARS-CoV-2 drugs. This review systematically discusses the current progress regarding potential anti-SARS-CoV-2 natural products and natural-product-inspired small molecules.

Promising Natural Products for Treating SARS-CoV-2 Infection {#s2}
============================================================

Natural products possess tremendous structural diversity and unique chemical diversity, and they continue to serve as excellent starting points for inspiring new drug discovery ([@B68]). The history of the modern pharmaceutical industry includes many stories about how natural products profoundly inspired drug discovery ([@B46]). With the current technological advances, natural products remain potentially transformative drugs for many health conditions. The growing understanding of efficient antiviral drug development has led to the exploration of natural products as an important tactic for identifying effective COVID-19 treatments.

Carolacton, produced by the myxobacterium *Sorangium cellulosum*, is an antibacterial macrolide keto-carboxylic acid ([**Figure 1A**](#f1){ref-type="fig"}) ([@B34]). *In vitro*, it demonstrates significant bioactivity against the human pathogen *Streptococcus mutans* by reducing the number of viable cells in biofilms ([@B25]), and it has been found to be a methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) inhibitor ([@B4]). SARS-CoV-2 may have originated in bats ([@B69]) (as a study has shown that its genome is similar to that of the bat coronavirus RaTG13, with 96.2% identity ([@B95])) and, very recently, Tan's group demonstrated that MTHFD1 is a critical host factor for the viral RNA replication of a broad spectrum of viruses in both bats and humans ([@B4]). Based on in-depth research, Tan's group demonstrated that MTHFD1 is a potential target for developing anti-SARS-CoV-2 agents and that the MTHFD1 inhibitor carolacton strongly inhibited SARS-CoV-2 replication in Vero cells at a half maximal inhibitory concentration (IC~50~) of as low as 0.14 μM and a moderate cytotoxicity (50% cytotoxic concentration \[CC~50~\] \>0.80 μM) ([@B4]). Thus, there is hope that this antimicrobial natural product may be useful in the COVID-19 epidemic.

![Promising natural products for treating COVID-19. **(A)** Carolacton was isolated from the myxobacterium *Sorangium cellulosum*. **(B)** Homoharringtonine was isolated from the plant *Cephalotaxus harringtonii*. **(C)** Emetine was isolated from the plant *Psychotria ipecacuanha*.](fphar-11-01013-g001){#f1}

Regarding the total synthesis of carolacton, three examples of milligram-scale processes have been reported. In 2012, Kirschning's group ([@B63]) reported on the first total synthesis of carolacton (with an overall yield of 4.3%) on an 8.5-mg scale in 22 linear steps. The key transformations involved asymmetric Nozaki-Hiyama-Kishi cross-coupling and Negishi-Fu coupling as well as the metal-mediated Ley aldol reaction, Duthaler-Hafner aldol reaction, Marshall reaction, and Breit's substitution. Two years later, Phillips's group and Wuest's group ([@B29]) collaboratively developed an efficient synthesis of carolacton (with an overall yield of 7.9%) on a 4.0-mg scale in just 14 linear steps. This synthesis process involved ring-closing metathesis (RCM), selective reduction, Leighton crotylation, and Steglich esterification. In 2017, Goswami's group ([@B43]) reported a third total synthesis (with an impressive overall yield of 18.8%) on a 7.1-mg scale in just 13 linear steps. The key strategies included Urpi acetal aldol reaction, β-hydroxy elimination, intermolecular esterification, and RCM. The three elegant synthesis strategies for producing carolacton are shown in [**Figure 2A**](#f2){ref-type="fig"}. However, in the current research and clinical contexts, the development of a ton-scale process to synthesize carolacton is urgently needed.

![Key strategies in the synthesis of carolacton and homoharringtonine. **(A)** Synthetic strategies of carolacton by Kirschning's group, Phillips's group and Goswami's group, respectively. **(B)** Synthetic strategies of homoharringtonine by Gin's group and Beaudry's group, respectively.](fphar-11-01013-g002){#f2}

Homoharringtonine (omacetaxine) is a natural product that was isolated from the plant *Cephalotaxus harringtonii* in 1970 ([@B59]). It was approved by the US Food and Drug Administration (FDA) in 2012 as an effective anti-cancer agent to treat chronic myeloid leukemia ([**Figure 1B**](#f1){ref-type="fig"}) ([@B50]). Additionally, it exhibits broad-spectrum activities against viruses, such as mouse hepatitis virus (MHV) at an IC~50~ of 0.012 μM ([@B14]), herpes simplex virus type 1 (HSV-1) at an IC~50~ of 0.14 μM ([@B20]), foot and mouth disease virus (FMDV) at an IC~50~ of 3.05 μM ([@B27]), and echovirus 1 (EV1) at a half maximal effective concentration (EC~50~) of 0.12 μM ([@B3]). Two elegant milligram-scale total syntheses of homoharringtonine have been reported by Gin's group ([@B22]) and Beaudry's group ([@B38]), respectively ([**Figure 2B**](#f2){ref-type="fig"}). In 2008, Gin's group reported a novel total synthesis of homoharringtonine on an 8.5-mg scale, using aziridine rearrangement and 1,3-dipolar cycloaddition as key strategies. In 2019, Beaudry's group developed an excellent total synthesis of homoharringtonine involving 12 linear steps on a 2.4-mg scale. The key strategies were oxidative furan ring opening with spontaneous transannular Mannich reaction as well as the Noyori hydrogenation reaction.

The tetrahydroisoquinoline alkaloid emetine is an older natural product that has potential cardiotoxicity and was isolated from the plant *Psychotria ipecacuanha* ([**Figure 1C**](#f1){ref-type="fig"}) ([@B83]). As a protein synthesis inhibitor, emetine has been widely used in pharmacology ([@B2]). Furthermore, emetine has recently been recognized as a promising broad-spectrum antiviral drug with *in vitro* activity against multiple viruses, including MHV-A59 at an EC~50~ of 0.12 μM ([@B67]), severe acute respiratory syndrome coronavirus (SARS-CoV) at an EC~50~ of 0.051 μM ([@B21]), Middle East respiratory syndrome coronavirus (MERS-CoV) at an EC~50~ of 0.014 μM ([@B21]), and Ebola virus (EBOV) at an IC~50~ of 0.017 μM ([@B89]). Very recently, Peterson's group showed that emetine concentrations could be 300 times higher in the lungs compared to in the blood, and emetine may achieve therapeutic concentrations at viral infection sites, especially in the lungs ([@B8]).

Yen's group recently revealed that both homoharringtonine and emetine could effectively inhibit the replication of SARS-CoV-2 in Vero E6 cells at an EC~50~ of 2.55 and 0.46 μM, respectively ([@B17]). Additionally, the combination of emetine and the C-nucleoside analog GS-5734 exhibited a synergistic inhibitory effect against SARS-CoV-2 replication ([@B17]). Multiple lines of evidence have shown the potential usefulness of homoharringtonine and emetine as treatments for viral infections, but further research is needed to explore whether they exhibit anti-SARS-CoV-2 activity *in vivo*.

The bisbenzylisoquinoline alkaloid cepharanthine is a natural product isolated from the plant *Stephania cephalantha*, which is used as a traditional herbal medicine ([**Figure 3**](#f3){ref-type="fig"}) ([@B6]). Specifically, this approved drug has significant bioactivity against several diseases, with anti-viral, anti-malarial, and anti-cancer effects ([@B23]). It has IC~50~ values of 0.026 μM and 9.5 μg/mL against HIV-1 ([@B55]) and SARS-CoV ([@B93]), respectively. Furthermore, it dramatically blocked the viral replication in human coronavirus OC43 (HCoV-OC43)-infected MRC-5 human lung cells (with an IC~50~ of 0.83 μM) and inhibited viral S and N protein expression ([@B41]). Watashi's group recently revealed that cepharanthine could effectively inhibit SARS-CoV-2 replication *in vitro* with an EC~50~ at 0.35 μM with minimal toxicity (selectivity index \>70) ([@B54]). It is worth noting that cepharanthine is an approved drug with a good safety profile, highlighting a new potential role for cepharanthine regarding inhibiting SARS-CoV-2 replication.

![Promising natural product cepharanthine for treating COVID-19 (image reproduced from ref. 38, bioRxiv, doi: 10.1101/2020.04.14.039925).](fphar-11-01013-g003){#f3}

There are currently no data on drug--drug interactions involving the abovementioned natural products ([@B75]), and close attention should be paid to these interactions during therapeutic use because drug--drug interactions will play significant roles in the safety and effectiveness of anti-COVID-19 agents.

Promising Natural Product-Inspired Agents for Treating SARS-CoV-2 Infection {#s3}
===========================================================================

Ivermectin (brand name: Stromectol) is a landmark broad-spectrum anti-parasitic drug that was developed by Ōmura's group along with Merck Sharp and Dohme Research Laboratories in 1978 ([@B10]). It has been demonstrated to be highly effective (94.9% efficacy at 24 hours and 73.8% efficacy at 2 weeks) as an oral drug for the treatment of head lice ([@B57]). Ivermectin is the semisynthetic 22,23-dihydro derivative of the natural product avermectin B~1~ (B~1a~ and B~1b~), which is produced by *Streptomyces avermitilis* ([**Figure 4**](#f4){ref-type="fig"}) ([@B12]). Ivermectin is one of the most widely used antibiotics for both animals and humans, and the researchers who discovered it received the Nobel Prize in Physiology or Medicine in 2015 ([@B13]).

![Promising natural-product-inspired ivermectin for treating COVID-19.](fphar-11-01013-g004){#f4}

The use of ivermectin is currently being expanded. For example, Wagstaff's group highlighted that ivermectin is highly effective at controlling SARS-CoV-2 RNA replication *in vitro*, with a 5000-fold reduction in the virus within 48 hours ([@B11]). Recently, Lohmer's group found that a single oral dose of ivermectin is unlikely to reach the IC~50~ (2.5 μM) in the lungs (predicted lung concentration: 0.0857 μM), and they suggested that combination therapy or inhaled treatment (to increase the concentration in the lungs) could be considered as potential solutions ([@B64]). Nevertheless, its safety in humans has been continuously documented ([@B9]), and it is hoped that it will become a key component of COVID-19 treatment regimens.

The C-nucleoside analog GS-5734 (remdesivir), a broad-spectrum antiviral agent developed by Gilead Sciences ([@B81]), exhibited promising clinical efficacy in the treatment of the first US case of SARS-CoV-2 infection ([@B30]). Initial research on synthesizing GS-5734 (which is a prodrug) began with structural modification of tubercidin (an antibiotic and adenosine analog that is isolated from *Streptomyces tubercidicus*) by replacing the C-N linkage with a C-C bond to create 4-aza-7,9-dideazaadenosine ([**Figure 5**](#f5){ref-type="fig"}) ([@B58]). 4-aza-7,9-dideazaadenosine has equal cytotoxicity against HL-60 cells to tubercidin (50% infectious does \[ID~50~\] = 0.82 nM) and increased hydrolytic stability ([@B58]).

![Promising natural-product-inspired GS-5734 for treating COVID-19 (image reproduced with permission from ref. 54, Acta Pharm. Sin. B, 2020, 10, 766-788).](fphar-11-01013-g005){#f5}

However, an important contribution to antiviral drug design is 1'-CN substituted Nuc, which can be viewed as a new structure that was inspired by the natural cyanide toyocamycin (isolated from *Streptomyces toyocmnsis*) ([@B53]). Nuc strongly inhibits hepatitis C virus *in vitro* (EC~50~ = 4.1 μM) ([@B16]). The active form of Nuc in virus-infected cells has been reported to be GS-441524, but the monophosphate conversion of Nuc to GS-441524 is a rate-limiting step ([@B81]). To overcome this issue, the monophosphorylated prodrug GS-5734 was developed to achieve better cellular uptake *in vivo* ([@B81]).

GS-5734 has been recognized as a promising broad-spectrum antiviral drug against multiple viruses including SARS-CoV (EC~50~ = 69 nM) ([@B65]) and MERS-CoV (EC~50~ = 20 nM) ([@B65]). Furthermore, Xiao's group ([@B80]) and Yen's group ([@B17]) recently revealed that GS-5734 is highly effective against SARS-CoV-2 infection *in vitro* (EC~50~ = 0.77 μM, viral load fitted in linear scale; or EC~50~ = 23.15 μM, viral load fitted in logarithmic scale) and has low toxicity (selectivity index \>130). Regarding the mechanism of action, Li's group highlighted that GS-5734 can bind to the RNA-binding channel of the SARS-CoV-2 RNA-dependent RNA polymerase ([@B85]) ([**Figure 5**](#f5){ref-type="fig"}). The 1'-ribose CN substitution observed in GS-5734 plays an important role in inhibiting the viral RNA replication of SARS-CoV-2 ([@B94]).

Notably, since 2016, GS-5734 has been reported to be safe and exhibit clinical efficacy against EBOV infection ([@B32]; [@B19]) and SARS-CoV-2 infection ([@B7]; [@B30]). On April 10, 2020, Gilead Sciences reported that 68% of patients with severe COVID-19 who were treated with GS-5734 (via the compassionate use program) exhibited clinical improvement, and no new safety issues were detected ([@B28]). In addition, in May, 2020, the US FDA issued an emergency use authorization (EUA) for GS-5734 for treating SARS-CoV-2 infection ([@B51]). To increase the efficiency of pharmaceutical research on GS-5734, researchers at Gilead Sciences developed a scalable process for synthesizing GS-5734 ([@B81]) ([**Figure 6**](#f6){ref-type="fig"}). Currently, there are no drug--drug interaction data on GS-5734 ([@B72]), but the potential for clinically significant interactions is low ([@B75]). It is hoped that GS-5734 will be confirmed to be a safe and effective drug against SARS-CoV-2.

![Gram-scale synthesis of GS-5734.](fphar-11-01013-g006){#f6}

The N-nucleoside analog EIDD-2801, a promising orally bioavailable antiviral agent, was discovered by Plemper's group at Emory University ([@B76]). Initial research on the synthesis of EIDD-2801 began with structurally modifying the broad-spectrum antiviral agent *N* ^4^-hydroxycytidine (NHC, EIDD-1931) ([@B1]), which was in turn derived from the essential natural product uridine found in human plasma ([**Figure 7**](#f7){ref-type="fig"}) ([@B88]).

![Promising natural-product-inspired EIDD-2801 for treating COVID-19.](fphar-11-01013-g007){#f7}

More recently, researchers at Emory University reported a scalable process for synthesizing EIDD-2801 ([@B56]) ([**Figure 8**](#f8){ref-type="fig"}). There is currently widespread interest in the use of EIDD-2801 as a promising anti-COVID-19 agent ([@B61]). Baric's group ([@B16]) highlighted that EIDD-1931 is very effective at controlling SARS-CoV-2 replication. EIDD-1931 exhibited potent anti-SARS-CoV-2 activity in Calu-3 cells (IC~50~ = 0.08 μM) and Vero cells (IC~50~ =0.30 μM), with no observable cytotoxicity at doses of up to 5 μM ([@B61]). Furthermore, EIDD-2801 is an orally bioavailable prodrug that is efficiently hydrolyzed *in vivo* and it exhibits remarkable selectivity (therapeutic window \>1713) ([@B66]).

![Gram-scale synthesis of EIDD-2801.](fphar-11-01013-g008){#f8}

In addition, Baric's group showed that EIDD-2801 significantly improved the pulmonary function of mice infected with MERS-CoV or SARS-CoV ([@B66]). Thus, EIDD-2801 has demonstrated potential effectiveness, even though there is a lack of good evidence in humans. It is hoped that researchers will work to overcome the obstacles (such as produced on a manufacturing scale, efficacy and safety *in vivo*) to allow it to be assessed in clinical research.

Other Small Molecules With *In Vitro* Activity Against SARS-Cov-2 {#s4}
=================================================================

Growing understanding of efficient antiviral drug development has led to the use of small molecules being recognized as an important potential tactic for treating COVID-19. Rao's group ([@B36]) showed that the organoselenium compound ebselen ([**Table 1**](#T1){ref-type="table"}) and other inhibitors of the SARS-CoV-2 main protease (M^pro^) exhibited potent activities, with IC~50~ values at micromolar or sub-micromolar levels (0.67--21.4 μM). Ebselen is highly effective at inhibiting SARS-CoV-2 infection (EC~50~ = 4.67 μM) and has low toxicity (median lethal dose \[LD~50~\] in rats \>4,600 mg/kg). Most importantly, its safety in humans has been continuously evaluated in multiple clinical trials ([@B40]). Besides the abovementioned small molecules, several other natural products and natural product-inspired potential small molecules have also exhibited notable anti-SARS-CoV-2 activities ([**Table 1**](#T1){ref-type="table"}).

###### 

Other small molecules with *in vitro* activity against SARS-Cov-2.

  No.   Name                     Structure                      EC~50~ or IC~50~ (μM)   SI       Ref.
  ----- ------------------------ ------------------------------ ----------------------- -------- ----------
  1     Abiraterone acetate      ![](fphar-11-01013-g010.jpg)   1.94                    47.6     ([@B92])
  2     ALLM                     ![](fphar-11-01013-g011.jpg)   2.07                    48.3     ([@B49])
  3     Amodiaquine              ![](fphar-11-01013-g012.jpg)   4.20                    \>7.1    ([@B31])
  4     Auranofin                ![](fphar-11-01013-g013.jpg)   1.40                    4.1      ([@B62])
  5     Azithromycin             ![](fphar-11-01013-g014.jpg)   2.12                    19.0     ([@B78])
  6     Baicalein                ![](fphar-11-01013-g015.jpg)   12.5-25.0               2.0      ([@B47])
  7     Baicalin                 ![](fphar-11-01013-g016.jpg)   10.27                   19.0     ([@B71])
  8     Boceprevir               ![](fphar-11-01013-g017.jpg)   1.90                    52.6     ([@B49])
  9     Carmofur                 ![](fphar-11-01013-g018.jpg)   24.30                   5.4      ([@B37])
  10    Cinanserin               ![](fphar-11-01013-g019.jpg)   20.61                   9.7      ([@B36])
  11    CVL218                   ![](fphar-11-01013-g020.jpg)   5.12                    17.8     ([@B26])
  12    Digitoxin                ![](fphar-11-01013-g021.jpg)   0.23                    214.1    ([@B35])
  13    Digoxin                  ![](fphar-11-01013-g022.jpg)   0.19                    256.6    ([@B35])
  14    Diiodohydroxyquinoline   ![](fphar-11-01013-g023.jpg)   1.38                    \>72.5   ([@B31])
  15    Ebselen                  ![](fphar-11-01013-g024.jpg)   4.67                    --       ([@B36])
  16    Fluspirilene             ![](fphar-11-01013-g025.jpg)   3.16                    9.6      ([@B82])
  17    GC-376                   ![](fphar-11-01013-g026.jpg)   3.37                    29.7     ([@B49])
  18    Hexachlorophene          ![](fphar-11-01013-g027.jpg)   0.90                    21.6     ([@B35])
  19    MDL28170                 ![](fphar-11-01013-g028.jpg)   0.49                    204.0    ([@B49])
  20    Nafamostat               ![](fphar-11-01013-g029.jpg)   0.0022                  11363    ([@B42])
  21    Nelfinavir               ![](fphar-11-01013-g030.jpg)   0.77                    83.1     ([@B54])
  22    Niclosamide              ![](fphar-11-01013-g031.jpg)   0.28                    176.7    ([@B35])
  23    Ouabain                  ![](fphar-11-01013-g032.jpg)   0.097                   515.5    ([@B35])
  24    Salinomycin sodium       ![](fphar-11-01013-g033.jpg)   0.24                    211.0    ([@B35])
  25    S312                     ![](fphar-11-01013-g034.jpg)   1.55                    \>64.6   ([@B87])
  26    S416                     ![](fphar-11-01013-g035.jpg)   0.017                   \>5882   ([@B87])

Drug development carries high risks. For example, although the approved protease inhibitors lopinavir and ritonavir ([**Figure 9A**](#f9){ref-type="fig"}) were thought to be potentially effective against SARS-Cov-2 (as they have been reported to be active against SARS^6^), Wang's group showed that lopinavir combined with ritonavir does not seem to be highly effective in patients with COVID-19 ([@B15]).

![Other small molecules for treating COVID-19. **(A)** Unsuccessful attempt of lopinavir and ritonavir to treat COVID-19. **(B)** Regulators split on chloroquine and hydroxychloroquine to treat COVID-19.](fphar-11-01013-g009){#f9}

Chloroquine and hydroxychloroquine ([**Figure 9B**](#f9){ref-type="fig"}) have garnered considerable attention due to their ability to effectively inhibit SARS-CoV-2 ([@B88]; [@B48]; [@B90]). For example, Xiao's group ([@B85]) showed that chloroquine potently blocked SARS-CoV-2 infection at a low concentration *in vitro* (EC~50~ = 1.1 μM). Although the US FDA has authorized the use of chloroquine and hydroxychloroquine, the WHO has stated that the clinical data do not support their clinical use in COVID-19 patients ([@B33]; [@B73]). In addition, chloroquine can be lethal (narrow therapeutic window) in children, and caution is warranted when it is used for critical illness ([@B70]).

Conclusion and Outlook {#s5}
======================

Currently, global attention continues to be focused on COVID-19 due to its serious threat to public health. Scientists have discovered that SARS-CoV-2 has developed mutations (in 149 sites from the 103 sequenced SARS-Cov-2 strain) that have substantially changed its pathogenicity ([@B74]; [@B91]). Therefore, rapid discovery of safe, effective, and broad-spectrum anti-COVID-19 drugs is urgent. However, it is well-known that the development of a new drug usually takes more than 10 years ([@B5]). Very recently, potential anti-SARS-CoV-2 natural products and natural product-inspired small molecules have attracted significant attention due to their broad-spectrum antiviral activities. Here, we reviewed the research on potential landmark anti-SARS-CoV-2 natural products (carolacton, homoharringtonine, cepharanthine, and emetine) and natural product-inspired small molecules (ivermectin, GS-5734, EIDD-2801, and ebselen). In-depth research on potential anti-COVID-19 natural product-inspired small molecules has led to the development of multiple lines of evidence demonstrating their effects on SARS-CoV-2 infection ([@B24]; [@B60]; [@B77]; [@B84]; [@B86]).

While the current COVID-19 pandemic has led to more rapid natural product-based drug discovery and development, it is also worth noting that ton-scale total synthesis strategies for the abovementioned potential anti-SARS-CoV-2 natural products (such as carolacton and homoharringtonine) are urgently needed. However, significant challenges (for example, attainment of clinical evidence regarding the anti-SARS-CoV-2 effects of the agents in patients, and traditional drug development approach in SARS-CoV-2 is becoming untenable) will need to be overcome in order for successful clinical research to be completed. We hope that natural products and natural product-inspired small molecules will be shown to be safe and effective for treating SARS-CoV-2 infection.
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